Loading...
•
Dec 31, 2025
Ocugen Q4 2025 Earnings Report
Ocugen reported fourth quarter 2025 results with minimal revenue and continued operating losses while advancing its gene therapy pipeline.
Key Takeaways
Ocugen reported negative revenue for the fourth quarter driven by adjustments in collaborative arrangement revenue and posted a net loss as R&D spending increased to support clinical development programs. The company continued advancing multiple gene therapy candidates and ended the quarter with limited cash, supplemented by financing in early 2026 to extend its runway.
Negative collaborative arrangement revenue resulted in total Q4 revenue of -$193K.
Net loss widened to $17.71M as operating expenses increased year over year.
Research and development spending rose to $10.67M as clinical programs advanced.
Cash position declined significantly year over year, prompting new financing in January 2026.
Revenue by Segment
Forward Guidance
Management expects multiple clinical milestones over the next two years while financing activities are intended to extend the company’s operating runway into late 2026 or potentially 2027.
Positive Outlook
- OCU400 Phase 3 liMeliGhT trial enrollment completed with topline data expected in Q1 2027.
- OCU410ST Phase 2/3 trial nearing enrollment completion with interim data expected in Q3 2026.
- Positive preliminary Phase 2 data reported for OCU410 in geographic atrophy.
- First regional licensing agreement for OCU400 signed with Kwangdong Pharmaceutical.
- Recent financing expected to extend operational runway into Q4 2026.
Challenges Ahead
- Company continues to report significant operating losses.
- Revenue generation remains minimal and dependent on collaborations.
- Cash balance declined sharply year over year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...